Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.59 |
| ▸ | NPC1 | O15118 | 7/20 | 0.59 |
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | CASP1 | P29466 | 2/20 | 0.59 |
| ▸ | CASP7 | P55210 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KLK7 | P49862 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679708 | 0.81 | KMT2A (0.61) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL10277579 | 0.81 | KDM4E (0.64) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL4960580 | 0.80 | NPC1 (0.77) | ALDH1A1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL4972667 | 0.80 | MEN1 (0.62) | ALDH1A1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL30569141 | 0.77 | NPC1 (0.73) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL27022341 | 0.77 | RAB9A (0.57) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL28167267 | 0.77 | MAPT (0.61) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL29639131 | 0.77 | RAB9A (0.57) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL1708566 | 0.76 | MAPT (0.57) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL30323221 | 0.75 | NPC1 (0.71) | KDM4EALDH1A1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-11938124-B2 | Combination therapy for treatment of cancer | PMV PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230049952-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | PMV PHARMACEUTICALS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230033324-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20230024905-A1 | USES OF P53 X-RAY CO-CRYSTAL STRUCTURES | PMV PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220315564-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938124-B2 | Combination therapy for treatment of cancer | TP53, KRAS, TP53BP1 | KDM4E 3164/4885ALDH1A1 2000/4885KMT2A 2148/4885 |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | KDM4E 2994/4885ALDH1A1 1538/4885KMT2A 2966/4885 |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | KDM4E 2994/4885ALDH1A1 1538/4885KMT2A 2966/4885 |
| US-20230049952-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | KDM4E 2994/4885ALDH1A1 1538/4885KMT2A 2966/4885 |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | KDM4E 3022/4885ALDH1A1 1428/4885KMT2A 2916/4885 |
| US-20230033324-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | KDM4E 3164/4885ALDH1A1 2000/4885KMT2A 2148/4885 |
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | TP53, TP53BP1, KRAS | KDM4E 3177/4885ALDH1A1 1835/4885KMT2A 3244/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | KDM4E 385/4885ALDH1A1 1944/4885KMT2A 601/4885 |
| US-20220315564-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | KDM4E 2994/4885ALDH1A1 1538/4885KMT2A 2966/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | KDM4E 3295/4885ALDH1A1 3910/4885KMT2A 3878/4885 |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | KDM4E 3164/4885ALDH1A1 2000/4885KMT2A 2148/4885 |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | KDM4E 2994/4885ALDH1A1 1538/4885KMT2A 2966/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | KDM4E 1371/4885ALDH1A1 4027/4885KMT2A 1704/4885 |
| US-20230024905-A1 | USES OF P53 X-RAY CO-CRYSTAL STRUCTURES | TP53, TP53BP1, MDM2 | KDM4E 3483/4885ALDH1A1 3539/4885KMT2A 4008/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | KDM4E 3177/4885ALDH1A1 1835/4885KMT2A 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.